More than 30 pharmaceutical companies will be listed on the Sci-tech Innovation Board by 2021, and the market value of four will exceed 30 billion yuan

As of December 12, 2021, the Science and Technology Innovation Board has gathered 75 biomedical companies, of which more than 30 biomedical companies will be listed in 2021
.
Statistics show that there will be 28 pharmaceutical and biological companies listed on the Sci-tech Innovation Board in 2020 and 14 in 2021
.
In 2021, there are 33 companies, and the data is higher than the previous two years.
From the perspective of market value, there are 13 companies with a new market value of more than 10 billion yuan
.
The market value of four pharmaceutical companies, including Novartis, Nanomicro Technology, Chengda Biological, and Beike Biological, is more than 30 billion yuan
.
The market value of Novartis: 46.
273 billion yuan.
According to data, Novozan will officially land on the Science and Technology Innovation Board on November 15, 2021.
The current new market value has reached 46.
273 billion yuan
.
Novartis is a biotechnology company engaged in technology research and development and product development of functional proteins and polymer organic materials such as enzymes, antigens, antibodies, etc.
Relying on the key common technology platform established independently, it has successively entered the business of biological reagents and in vitro diagnostics.
In the field of research and development of antibody drugs, it is one of the few domestic R&D and innovative enterprises that have both independent and controllable upstream technology development capabilities and terminal product production capabilities
.
Novartis currently has more than 200 genetic engineering recombinases and more than 1,000 high-performance antigens and monoclonal antibodies and other key raw materials, and has more than 500 end products, which can be widely used in scientific research, high-throughput sequencing, in vitro diagnostics, and medicine And vaccine research and development and animal quarantine and other fields
.
Among them, in the field of life sciences, the company has successfully launched many series of biological reagents including high-throughput sequencing library series, PCR series, qPCR series, molecular cloning series, reverse transcription series, and Bio-assay series
.
In the field of in vitro diagnostics, 8 series of POCT diagnostic reagents including cardio-cerebrovascular, inflammation and infection, prenatal and postnatal care, and gastric function have been launched
.
Nawei Technology Market Value: 35.
893 billion yuan Nawei Technology was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on June 23, 2021, and the current new market value has reached 35.
893 billion yuan
.
According to the data, Nanomicro Technology is a company specializing in the research and development, large-scale production, sales and application services of high-performance nano-microsphere materials, providing core microsphere materials and related technical solutions for customers in the fields of biomedicine, flat panel display, analysis and testing, and IVD.
Scheme of the enterprise
.
The company's products cover normal phase, reversed phase, HILIC, chirality, size exclusion, ion exchange, affinity, mixed mode and customized chromatography packing and chromatography media products, which can meet the requirements of organic chemicals, chiral drugs, natural purification of the broad requirements drugs, antibiotics, insulin, polypeptides, proteins, antibodies, nucleotides, vaccines, viruses and the like
.
Among them, the company's Nanomicro Technology high-performance chromatography packing products have broken the technical difficulties of precise preparation of microspheres, and have been widely used in domestic pharmaceutical companies and exported to Europe, the United States, Japan, South Korea and other countries on a large scale
.
Chengda Biologics market value: 32.
187 billion yuan Chengda Biologics was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on October 28, 2021, and its current new market value is 32.
187 billion yuan
.
Public information shows that Chengda Biologics is an enterprise in China focusing on the research and development, production and sales of human vaccines.
Over the years, it has insisted on independent innovation, maintained high R&D investment, and gradually grew into a global rabies vaccine giant, with core technologies breaking foreign monopolies
.
The sales scope of the human rabies vaccine (Vero cell), the core product of Chengda Biologics, covers nearly 2,000 district and county-level disease control centers across the country
.
Chengda Biologics has strong independent research and development capabilities, and has technological advantages in the subdivision and growth track of domestic rabies vaccines
.
The market value of Baike Biology: 32.
003 billion yuan.
Baike Biology was officially listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on June 25, 2021.
The current new market value is 32.
003 billion yuan
.
According to the data, Baike Biotechnology is an innovative biomedical company mainly dedicated to the prevention and treatment of infectious diseases.

.
Baike Biology currently has three approved vaccine products: varicella vaccine, rabies vaccine and freeze-dried nasal spray flu vaccine.
It also has 14 vaccines under development and 2 vaccines under development for the prevention and control of infectious diseases.
Source monoclonal antibodies, including live attenuated shingles vaccine, adsorption acellular DPT (three-component) combination vaccine, Haemophilus influenzae type b combination vaccine, fully human anti-rabies monoclonal antibody, fully human source anti-tetanus toxin monoclonal antibodies
.
The company has been committed to the R&D and industrialization of biological vaccines and biological drugs, and has gradually established a "technology platform for large-scale virus cultivation", "preparation and adjuvant technology platform", "genetic engineering technology platform" and "bacterial vaccine technology platform" And other four major technology platforms to form a complete innovation research and development system
.